Ying-Ang Ji

Ying-Ang Ji

Auto-generated profile, based on publicly available information

Ying-Ang Ji

Daping Hospital 1 Department of Urology , Chongqing, People’s Republic of China

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 February 2026 in Cancer Research
Verified
Journal Article
Open access
WLWeiming Luo
Weiming Luo
YWYapeng Wang
Yapeng Wang
HWHaitao Wang
Haitao Wang
YJYing-Ang Ji
Ying-Ang Ji
JZJian Zhang
Jian Zhang
QLQiuli Liu
Qiuli Liu
Immune checkpoint inhibitors (ICI) have transformed cancer therapy, yet their efficacy remains limited to a subset of patients, underscoring the need for robust predictive biomarkers and deeper mechanistic insights into treatment resistance. In this study, we identified a population of CCL5hiCD4+ T cells that were characterized by memory-like activation markers and strongly correlated with ICI therapeutic responses in bladder cancer. Functionally, these T cells enhanced antitumor immunity by promoting M1-like macrophage polarization through CCL5/CCR1 signaling. Importantly, tumor-derived prostaglandin E2 (PGE2) acted as a critical microenvironmental factor that suppressed the differentiation of CCR6hiCD4+ T cells into immunostimulatory CCL5hiCD4+ T cells, thereby driving resistance to ICI therapy. These findings extend the understanding of CD4+ T-cell heterogeneity and its role in shaping immune responses to ICI. By elucidating that CCL5hiCD4+ T cells enhance myeloid-mediated tumor control and that tumor-derived PGE2 disrupts CCL5hiCD4+ T-cell differentiation to promote immune evasion, this work highlights potential therapeutic strategies to improve ICI efficacy in bladder cancer. Significance: CCL5 hiCD4+ T cells with memory-like activated characteristics enhance antitumor immunity in bladder cancer by reprogramming macrophages, supporting the potential of these cells as biomarkers and targets to enhance immunotherapy efficacy.

17 June 2026
Verified
Other
Open access
WLWeiming Luo
Weiming Luo
YWYapeng Wang
Yapeng Wang
HWHaitao Wang
Haitao Wang
YJYing-Ang Ji
Ying-Ang Ji
JZJian Zhang
Jian Zhang
QLQiuli Liu
Qiuli Liu
Supplementary Figure S2. Single-cell analysis of bladder cancer identifies diverse cell types including distinct CD4 + T cell subsets. (A) Heatmap of top differentially expressed marker genes for each cell type in BLCA (left); dot plot comparing transcriptional profiles between CD4+ and CD8+ T cell subsets (right). (B) Bar graph showing the relative abundance of indicated cell subsets in BLCA. (C) Heatmap displaying expression patterns of CD4-3 subset-specific marker genes across CD4+ T cell subsets. (D) UMAP plots showing distinct CD4+ T cell subsets in human BLCA derived from the PRJNA662018 dataset (n = 11 samples). (E) Dot plot depicting the memory activated CD4+ T cell signature and the expression of selected CD4-3 marker genes across CD4 + T cell subsets in PRJNA662018 dataset. (F) Bar graph showing the relative abundance of indicated cell subsets in BLCA. (G) UMAP plots showing memory-activated CD4+ T cell signature scores across CD4+ T cell subsets. (H) Comparison of CD4 + T cell subsets in this study with published human CD4 + T cell states. (I) Dot plots depict the memory coinhibitory scores across CD4 + T cell subsets. (J) Violin plot showing expression of immune-checkpoint genes in tumor versus peritumoral tissues. (K) Volcano plot of differentially expressed genes in CCL5 hi-CD4 + T cells (tumor vs peritumoral tissues) with immune-checkpoint genes highlighted in red. (L) Differential proportion of CCL5 hi-CD4+ T cells between CR/PR and SD/PD groups in the IMvigor210 cohort. (M) Representative mIHC images and quantification of the proportion of CD4+CXCL13+ cells among total CD4+ T cells in CR (n = 12) versus non-CR (n = 28) patients. (CD4: green; CXCL13: red; nuclei: DAPI/blue). Scale bars: 50 μm. (N) Representative mIHC images and quantification of the proportion of CD4+FOXP3+ cells among total CD4+ T cells in CR (n = 12) versus non-CR (n = 28) patients. (CD4: green; FOXP3: red; nuclei: DAPI/blue). Scale bars: 50 μm. (O) Representative mIHC images and quantification of the proportion of CD8+ cells among total cells in CR (n = 12) versus non-CR (n = 28) patients. (CD8: white; DAPI/blue). Scale bars: 3 mm. (P) UMAP plots showing distinct CD4+ T cell subsets in merged Daping Cohort 1 and Cohort 2. (Q) UMAP plots showing distinct CD4+ T cell subsets in Daping Cohort 2. (R) PCA projection showing the similarity of CD4+ T cell subset between Daping Cohort 2 and Cohort 1. (S) The proportion of each subset within CD4 + T cells across samples in Daping Cohort 2. (T) Differential abundance of memory activated CD4 + T cells between CR/PR and SD/PD groups in SKCM (melanoma) and STAD (gastric cancer). (U) Violin plot depicting the expression of selected CCL5 hi-CD4 marker genes and Cxcr6 across CD4 + T cell subsets in mouse BLCA. (V) Dot plot depicting the expression of CXCR6 across CD4 + T cell subsets in human BLCA. (W) Flow cytometry plot showing the sorting strategy for CCL5 hi-CD4 cells. (X) Schematic workflow for isolation of CD45.1 +CD25 -CXCR6 +CD4 + T cells, adoptive transfer into CD45.2 recipients and analyzed at various time points. (Y) Representative flow cytometry plots showing CD45.1 vs CD45.2 progression from days 1 to 5, and quantification of the CD45.1 + :CD45.2 + ratio within CD4 +FOXP3 -CCL5 + T cells. P values were calculated as follows: two-sided unpaired t-test (B, F, M, N, and O), two-sided unpaired Wilcoxon rank-sum test (L, T).

17 June 2026
Verified
Other
Open access
WLWeiming Luo
Weiming Luo
YWYapeng Wang
Yapeng Wang
HWHaitao Wang
Haitao Wang
YJYing-Ang Ji
Ying-Ang Ji
JZJian Zhang
Jian Zhang
QLQiuli Liu
Qiuli Liu
Immune checkpoint inhibitors (ICI) have transformed cancer therapy, yet their efficacy remains limited to a subset of patients, underscoring the need for robust predictive biomarkers and deeper mechanistic insights into treatment resistance. In this study, we identified a population of CCL5hiCD4+ T cells that were characterized by memory-like activation markers and strongly correlated with ICI therapeutic responses in bladder cancer. Functionally, these T cells enhanced antitumor immunity by promoting M1-like macrophage polarization through CCL5/CCR1 signaling. Importantly, tumor-derived prostaglandin E2 (PGE2) acted as a critical microenvironmental factor that suppressed the differentiation of CCR6hiCD4+ T cells into immunostimulatory CCL5hiCD4+ T cells, thereby driving resistance to ICI therapy. These findings extend the understanding of CD4+ T-cell heterogeneity and its role in shaping immune responses to ICI. By elucidating that CCL5hiCD4+ T cells enhance myeloid-mediated tumor control and that tumor-derived PGE2 disrupts CCL5hiCD4+ T-cell differentiation to promote immune evasion, this work highlights potential therapeutic strategies to improve ICI efficacy in bladder cancer.Significance:CCL5hiCD4+ T cells with memory-like activated characteristics enhance antitumor immunity in bladder cancer by reprogramming macrophages, supporting the potential of these cells as biomarkers and targets to enhance immunotherapy efficacy.

17 June 2026
Verified
Other
Open access
WLWeiming Luo
Weiming Luo
YWYapeng Wang
Yapeng Wang
HWHaitao Wang
Haitao Wang
YJYing-Ang Ji
Ying-Ang Ji
JZJian Zhang
Jian Zhang
QLQiuli Liu
Qiuli Liu
Supplementary Figure S5. The relationship between tumor-derived PGE2, CCL5 hi-CD4 + T cell infiltration in bladder cancer. (A) Patient stratification by CCR6 hi-CD4 + T cell and CCL5 hi-CD4 + T cell abundance (group A-D). (B) Abundance of memory activated CD4 + T cells (left) and memory resting CD4 + T cells (right) in group B and C. (C) Shared upregulated genes (n = 45 genes) in group C versus group B across TCGA (n = 323 genes) and IMvigor210 (n = 91 genes) cohorts. (D) Expression of the 45 upregulated genes across cell subsets within tumor microenvironment. (E) UMAP plots showing distinct tumor cell subsets in human BLCA. (F) Dot plot of selected top differentially expressed marker genes for each tumor subset. (G) UMAP plots showing selected gene signature scores across tumor cell subsets. (H) Differential cell-cell communication networks between tumor cells of distinct scoring groups and CCR6 hi-CD4 + T cells. (I) Kaplan-Meier survival analysis stratified by PGE2 score levels. (J) ELISA showing the difference in PGE2 levels between CR (n = 4) and non-CR (n = 6) patients. (K) Correlation of PGE2 scores with CCR6 hi-CD4 differentiation-related tumor genes score. (L) Heatmap showing the enrichment of PGE2 score across tumor subsets and cell populations within tumor microenvironment. (M) Representative mIHC images showing COX2 localization to the tumor epithelium (COX2: red; CK8/18: yellow); scale bars: 100 μm. (N) Representative mIHC images showing the spatial relationship between CCL5 hi-CD4 + T cells (CCL5 +CD4 + , white arrows) and tumor with different COX2 expression levels; scale bars: 800 μm. (O) Quantification of the proportion of CCL5 +CD4 + cells among CD4 + T cells in tumor regions with high versus low PGE2 levels. (P) Validation of COX2 protein levels in MB49 cells after COX2 knockdown. (Q) Representative flow cytometry plots comparing the proportion of CCL5 + or CCR6 + cells within CD25 -CD4 + T cells and of M1-macrophage (CD86 +CD206 -F4/80 + ) across treatment groups. (R) Representative flow cytometry plots showing the proportion of CCL5 + cells within CD45.1 +FOXP3 -CD4 + T cells across treatment groups at the indicated days after adoptive transfer of CD45.1 +CD25 -CCR6 +CD4 + T cells. (S) Representative flow cytometry plots comparing the proportion of CCL5 + cells among all CD4 + T cells across different treatment groups. P values were calculated as follows: two-sided unpaired Wilcoxon rank-sum test (B), log-rank test (I), two-sided unpaired t-test (J, O) and Spearman correlation (K)

17 June 2026
Verified
Other
Open access
WLWeiming Luo
Weiming Luo
YWYapeng Wang
Yapeng Wang
HWHaitao Wang
Haitao Wang
YJYing-Ang Ji
Ying-Ang Ji
JZJian Zhang
Jian Zhang
QLQiuli Liu
Qiuli Liu
Supplementary Figure S3. CCL5 hi-CD4 + T cells enhance M1 macrophage infiltration. (A) Dot plot showing CCL5 expression across cell subsets within tumor microenvironment. (B) Representative flow cytometry plots showing the proportions of non-T cells (CD4 -CD8 -), CD4 + cells, and CD8 + cells across different CCL5 expression levels. (C) Quantification of CD8 +CD4 + , CD4 + , CD8 + , and CD4 -CD8 - cell proportions within CCL5-high-expression cells (n = 3/group). (D) CellChat analysis predicting the interaction likelihood between CCL5 hi-CD4+ T cells (source) and cell subsets within tumor microenvironment (target). Dot size, color intensity, and line width represent the number of interactions. (E) UMAP plots showing distinct myeloid subsets in human BLCA. (F) Dot plot of top differentially expressed marker genes for each myeloid subset. (G) Difference in proportion of CD68+CD86+ cells among total CD68+ cells between CR and non-CR groups (left, n = 12 CR samples; right, n = 28 non-CR samples). (H) Correlation between CCL5 hi-CD4 + T cells and M1 macrophages across TCGA pan-cancer datasets. (I) Representative mIHC images from each treatment group showing F4/80+CD86+ dual-positive cells (F4/80: magenta; CD86: cyan; nuclei: DAPI/blue); scale bars: 50 μm. (J) Quantification of F4/80+CD86+ cells within total F4/80+ populations (n = 7 mice/group). (K) Representative flow cytometry plots showing M1 macrophages (CD206 -CD86 + F4/80 + ) and M2 macrophages (CD206 +CD86 -F4/80 + ) subsets across treatment groups. (L) Differences in M2 macrophage infiltration among treatment groups (n = 5–7 mice/group). (M) Representative mIHC images from each treatment group showing CD8+ cells (CD8: yellow; nuclei: DAPI/blue); scale bars: 100 μm. (N) Quantification of CD8+ cells as a percentage of total cells across treatment groups (n = 7 mice/group). (O) Expression of canonical CCL5 receptors in human myeloid cell subsets. (P) Representative mIHC images showing spatial proximity between CCL5 hi-CD4 + T cells (CCL5 +CD4 + , yellow arrows) and CCR1 + M1-like macrophages (CCR1 +CD86 + , white arrows); scale bars: 50 μm. (Q) Expression of phenotypical markers (M2) on RAW264.7 cells co-cultured with CCL5 hi-CD4+ T cells or CCL5 hi-CD4+ T cells plus BX471. P values were calculated as follows: two-sided paired t-test (C), two-sided unpaired Wilcoxon rank-sum test (G), one-way ANOVA (J, N and Q), and Kruskal–Wallis tests (L).

17 June 2026
Verified
Other
Open access
WLWeiming Luo
Weiming Luo
YWYapeng Wang
Yapeng Wang
HWHaitao Wang
Haitao Wang
YJYing-Ang Ji
Ying-Ang Ji
JZJian Zhang
Jian Zhang
QLQiuli Liu
Qiuli Liu
Supplementary Figure S1. The abundance of memory activated CD4 + T predicts response to ICI therapy in bladder cancer. (A) Univariable Cox regression analysis of memory-activated CD4+ T cell abundance and clinical parameters for overall survival in the IMvigor210 cohort, showing hazard ratios (HR), 95% confidence intervals (CI), and P-values. (B) Bar plot comparing response rates (CR/PR vs SD/PD) across subgroups stratified by tumor mutational burden (TMB) status and memory activated CD4+ T cell infiltration levels. (C) The predictive value of memory activated CD4+ T cell is comparable to TMB and is enhanced when combined with TMB. P values were calculated as follows: Wald test (A), Fisher's exact test (B).